Guardant Health and COTA partner in advanced oncology R&D

Guardant Health (GH) announced a new partnership with COTA, a provider of real-world data and analytics for oncology, that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies. By gaining insights into how different patient populations respond to therapies in real-world settings, drug developers can facilitate biomarker discovery, refine clinical trials, accelerate approvals, and bring targeted, life-saving treatments to market more quickly. Guardant’s real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while COTA’s curated data tracks a patient’s complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens COTA’s data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers.